INMB

Over the past six months, INmune Bio, Inc.'s stock price experienced a significant increase of +107.34% as of September 2026. Key events include regulatory advancements such as Ebstrocel™ (CORDStrom platform) moving towards European Marketing Authorization in August 2026, targeting UK MAA in Q4 2026 and EU MAA/U.S. BLA in Q1 2027, and the FDA granting Fast Track designation to XPro™ for early Alzheimer's disease. Financially, the company received approximately $4.6 million in R&D rebates from Australia and the United Kingdom in July 2026, announced its Second Quarter 2026 results in August 2026, and appointed a new board member in September 2026. The company also adjusted warrant prices and extended expiry dates to generate cash. Clinical trial progress includes the CORDStrom™ program in RDEB being on target for regulatory submissions, XPro™ receiving FDA alignment for an adaptive Phase 2b/3 registrational pathway in early Alzheimer's Disease, and the INKmune® CARE-PC trial meeting its primary and two of three secondary endpoints. The company was also scheduled to present at the H.C. Wainwright Global Investment Conference in September 2026.